Collectively, data here discussed suggest that PD-L1 carried by sEVs actively contributes to attenuate anti-tumor immunity, is the mediator of immunotherapy resistance and can be considered a good diagnostic and therapeutic biomarker. The gene discussed is CD274; the disease is neoplasm.